Impact of Comorbid Pathology on the Incidence of Hospitalization in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
PDF

Keywords

COPD
exacerbation
hospitalization
comorbid states

How to Cite

Hashynova, K. Y. (2014). Impact of Comorbid Pathology on the Incidence of Hospitalization in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD). Galician Medical Journal, 21(3), 25-29. Retrieved from https://ifnmujournal.com/gmj/article/view/226

Abstract

The objective of the work was to define impact of comorbid pathology on the increase of the risk of rehospitalization due to COPD acute exacerbation. Materials and methods. There was carried out retrospective analysis of case histories of patients with COPD exacerbation, hospitalized to the in-patient department over the three years’ period.  Medical history, results of spirography and general clinical investigations on admission to the in-patient department were studied. Results. All patients were allocated in two groups: the first group comprised 112 people (those who have been hospitalized one time) and the second one comprised 19 people (those who have been hospitalized due to COPD exacerbation twice or more times during the three years’ period). It was established that in the group ІІ there were significantly more patients with some or other comorbidity. Cardiovascular pathology, namely ischemic heart disease, was the most prevalent pathology among patients of both (34.82 ± 4.50 and 63.16±11.07 % correspondingly, р = 0.019) groups. Patients of the group ІІ suffered more often from diabetes mellitus (р = 0.039). Conclusions. Prevalent majority of COPD patients, hospitalized due to exacerbation, had at least one more disease. Concomitant cardiovascular pathology was the most prevalent. Presence of even one comorbid state increases the risk of future repeated severe COPD exacerbation, which will require in-patient treatment. Presence of ischemic heart disease and diabetes mellitus are the gravest among the risk factors of future hospitalizations. It is recommended to record data on existing comorbid pathology into medical documentation of COPD patients.

PDF

References

Mostovyi Yu.M., Konstantynovych-Chіcherelio T.V., Koloshko O.M., Rasputіna L.V. The instrumental methods for evaluating the respiratory function in patients with bronchopulmonary diseases: methodical guide. Vіnnytsia. 2000; 36.

Mostoviy Yu.M., Rasputіna L.V. Chronic obstructive pulmonary disease and arterial hypertension: peculiarities of clinical course, therapeutic approach. Ukraiinskyi pulmonolohіchnyi zhurnal. 2010; 1: 23.

Ostrovskyi М.М., Herych P.R. The question of polymorbidity and comorbidity in patients with COPD. Ukraiinskyi pulmonolohіchnyi zhurnal. 2011; 4: 19-24.

On approval of clinical protocols of medical care in the specialty pulmonology: the Order Ministry of Health of Ukraine № 128 from 19.03. 2007.

On approval and implementation of medical and technological documents on standardization of medical care in chronic obstructive pulmonary disease: the Order Ministry of Health of Ukraine № 555 from 27.06. 2013.

Rasputіna L.V. Non-specific lung diseases and cardio-vascular comorbidity in medical practice. Ukraiinskyi pulmonolohіchnyi zhurnal. 2011; 4: 25-7.

Rebrova О.Yu. Statistical analysis of medical data. Application of software package STATISTICA. М. Mediasfera. 2002; 312.

Feshchenko Yu.I. New edition of Global Initiative for Chronic Obstructive Lung Diseases. Ukraiinskyi pulmonolohіchnyi zhurnal. 2012; 2: 6-8.

Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. European Respiratory Journal. 2009; 33: 1165-1185.

Bravein A.A., Lukasz K., Arvin P. et al. Prediction model for COPD readmissions: catching up, catching our breath, and improving a national problem. Journal of Community Hospital Internal Medicine Perspectives. 2012; 2 (1): 302–304.

Elixhauser A. Readmissions for Chronic Obstructive Pulmonary Disease, 2008. A. Elixhauser, D. Au. J. Podulka. HCUP Statistical Brief №121. September 2011. Agency for Healthcare Research and Quality, Rockville, MD. http:www.hcup-us.ahrq.gov.reports.statbriefs.sb121.pdf.

Fletcher C. M., Peto R., Tinker C. M., Speizer F. E. Natural history of chronic bronchitis and emphysema. Oxford: Oxford University Press. 1976; 272.

Foster T. S., Miller J. D., Marton J. P. et al Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD. 2006; 3: 211–218.

Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. WHO. 2011; http:www.goldcopd.com.

V. Brusasco et al. Series ATS/ERS task force: Standardization of lung function testing. European Respiratory Journal. 2005; 26: 319–338.

WHO/CDC. Assessing the iron status of populations: report of a joint World Health Organization/ Centres for Disease Control and Prevention technical consultation on the assessment of iron status at the population level, 2nded. Geneva. World Health Organization. 2007; http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/9789241596107.pdf

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.